Cyclic peptides as drugs for intracellular targets: the next frontier in peptide therapeutic development.
暂无分享,去创建一个
[1] Jan Baumbach,et al. From single drug targets to synergistic network pharmacology in ischemic stroke , 2019, Proceedings of the National Academy of Sciences.
[2] K. Hoehn,et al. Delivering bioactive cyclic peptides that target Hsp90 as prodrugs , 2019, Journal of enzyme inhibition and medicinal chemistry.
[3] Lichun Sun,et al. Drug discovery and drug marketing with the critical roles of modern administration. , 2018, American journal of translational research.
[4] Luis M Liz-Marzán,et al. Cellular Uptake of Nanoparticles versus Small Molecules: A Matter of Size. , 2018, Accounts of chemical research.
[5] Joshua A. Kritzer,et al. Cell Penetration Profiling Using the Chloroalkane Penetration Assay. , 2018, Journal of the American Chemical Society.
[6] H. Kessler,et al. Enhancing Oral Bioavailability of Cyclic RGD Hexa-peptides by the Lipophilic Prodrug Charge Masking Approach: Redirection of Peptide Intestinal Permeability from a Paracellular to Transcellular Pathway. , 2018, Molecular pharmaceutics.
[7] A. Yudin,et al. Development of Endocyclic Control Elements for Peptide Macrocycles. , 2018, Journal of the American Chemical Society.
[8] Jason E Gestwicki,et al. Inhibitors of protein-protein interactions (PPIs): an analysis of scaffold choices and buried surface area. , 2018, Current opinion in chemical biology.
[9] S. McAlpine,et al. Converting polar cyclic peptides into membrane permeable molecules using N‐methylation , 2018 .
[10] Daniel J. Sindhikara,et al. High throughput evaluation of macrocyclization strategies for conformer stabilization , 2018, Scientific Reports.
[11] Vasanthanathan Poongavanam,et al. Impact of Dynamically Exposed Polarity on Permeability and Solubility of Chameleonic Drugs Beyond the Rule of 5. , 2018, Journal of medicinal chemistry.
[12] Ji Hoon Lee,et al. Comparison of Cell Permeability of Cyclic Peptoids and Linear Peptoids. , 2018, ACS combinatorial science.
[13] D. Craik,et al. Conformational Flexibility Is a Determinant of Permeability for Cyclosporin. , 2018, The journal of physical chemistry. B.
[14] S. McAlpine,et al. Improving the Cell Permeability of Polar Cyclic Peptides by Replacing Residues with Alkylated Amino Acids, Asparagines, and d-Amino Acids. , 2018, Organic letters.
[15] Jayanta Chatterjee,et al. Increasing the bioactive space of peptide macrocycles by thioamide substitution , 2018, Chemical science.
[16] K. Goss,et al. Predicting apparent passive permeability of Caco-2 and MDCK cell-monolayers: A mechanistic model , 2017, PloS one.
[17] S. McAlpine,et al. Synthesis and Structure–Activity Relationships of Inhibitors That Target the C-Terminal MEEVD on Heat Shock Protein 90 , 2017, ACS medicinal chemistry letters.
[18] A. Mathiowetz,et al. Discovery of Potent and Orally Bioavailable Macrocyclic Peptide-Peptoid Hybrid CXCR7 Modulators. , 2017, Journal of medicinal chemistry.
[19] A. Ganesan,et al. Systematic Analysis of the Relationship among 3D Structure, Bioactivity, and Membrane Permeability of PF1171F, a Cyclic Hexapeptide with Paralyzing Effects on Silkworms. , 2017, The Journal of organic chemistry.
[20] Alexandre M J J Bonvin,et al. SpotOn: High Accuracy Identification of Protein-Protein Interface Hot-Spots , 2017, Scientific Reports.
[21] James C. Collins,et al. The Current State of Peptide Drug Discovery: Back to the Future? , 2017, Journal of medicinal chemistry.
[22] Horst Kessler,et al. Improving oral bioavailability of cyclic peptides by N-methylation. , 2017, Bioorganic & medicinal chemistry.
[23] Jolene L. Lau,et al. Therapeutic peptides: Historical perspectives, current development trends, and future directions. , 2017, Bioorganic & medicinal chemistry.
[24] C. Heinis,et al. Cyclic peptide therapeutics: past, present and future. , 2017, Current opinion in chemical biology.
[25] D. Mochly‐Rosen,et al. Peptides and peptidomimetics as regulators of protein-protein interactions. , 2017, Current opinion in structural biology.
[26] Martin J. Stoermer,et al. Orally Absorbed Cyclic Peptides. , 2017, Chemical reviews.
[27] T. Vorherr,et al. Modulation of Oral Bioavailability and Metabolism for Closely Related Cyclic Hexapeptides , 2017, International Journal of Peptide Research and Therapeutics.
[28] A. Mathiowetz,et al. Comparative pharmacokinetic profile of cyclosporine (CsA) with a decapeptide and a linear analogue. , 2017, Organic & biomolecular chemistry.
[29] S. Shuto,et al. Highly Conformationally Restricted Cyclopropane Tethers with Three-Dimensional Structural Diversity Drastically Enhance the Cell Permeability of Cyclic Peptides. , 2017, Chemistry.
[30] Yao Wang,et al. Redefining the Phenotype of Heat Shock Protein 90 (Hsp90) Inhibitors. , 2017, Chemistry.
[31] Honggang Cui,et al. Peptide–drug conjugates as effective prodrug strategies for targeted delivery , 2017, Advanced drug delivery reviews.
[32] A Ganesan,et al. Oral Administration of Peptide‐Based Drugs: Beyond Lipinski's Rule , 2016, ChemMedChem.
[33] Chad E. Townsend,et al. Passive Membrane Permeability in Cyclic Peptomer Scaffolds Is Robust to Extensive Variation in Side Chain Functionality and Backbone Geometry. , 2016, Journal of medicinal chemistry.
[34] T. Kodadek,et al. Cell-Permeable Peptides Containing Cycloalanine Residues. , 2016, Angewandte Chemie.
[35] Matthew R. Naylor,et al. Stereochemistry Balances Cell Permeability and Solubility in the Naturally Derived Phepropeptin Cyclic Peptides. , 2016, ACS medicinal chemistry letters.
[36] A. Liguori,et al. N-Methylated α-Amino Acids And Peptides: Synthesis And Biological Activity. , 2016, Mini reviews in medicinal chemistry.
[37] Serge Zaretsky,et al. Passive Membrane Permeability of Macrocycles Can Be Controlled by Exocyclic Amide Bonds. , 2016, Journal of medicinal chemistry.
[38] S. Vajda,et al. Quantifying the chameleonic properties of macrocycles and other high-molecular-weight drugs. , 2016, Drug discovery today.
[39] D. Scott,et al. Small molecules, big targets: drug discovery faces the protein–protein interaction challenge , 2016, Nature Reviews Drug Discovery.
[40] Paul W. Wojcik,et al. Peptide-based inhibitors of protein-protein interactions. , 2016, Bioorganic & medicinal chemistry letters.
[41] Mie Kristensen,et al. Applications and Challenges for Use of Cell-Penetrating Peptides as Delivery Vectors for Peptide and Protein Cargos , 2016, International journal of molecular sciences.
[42] S. McAlpine,et al. The first report of direct inhibitors that target the C-terminal MEEVD region on heat shock protein 90. , 2016, Chemical communications.
[43] M. Chung,et al. The Prodrug Approach: A Successful Tool for Improving Drug Solubility , 2015, Molecules.
[44] Jan Tavernier,et al. Modulation of Protein–Protein Interactions for the Development of Novel Therapeutics , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.
[45] Alessio Ciulli,et al. Cyclic and Macrocyclic Peptides as Chemical Tools To Recognise Protein Surfaces and Probe Protein–Protein Interactions , 2015, ChemMedChem.
[46] Alun Jones,et al. Flexibility versus Rigidity for Orally Bioavailable Cyclic Hexapeptides , 2015, Chembiochem : a European journal of chemical biology.
[47] D. Murray,et al. Romidepsin targets multiple survival signaling pathways in malignant T cells , 2015, Blood Cancer Journal.
[48] Chad E. Townsend,et al. Going Out on a Limb: Delineating The Effects of β-Branching, N-Methylation, and Side Chain Size on the Passive Permeability, Solubility, and Flexibility of Sanguinamide A Analogues. , 2015, Journal of medicinal chemistry.
[49] O. Koch,et al. Strukturbasierte Entwicklung von Protein-Protein-Interaktionsinhibitoren: Stabilisierung und Nachahmung von Peptidliganden , 2015 .
[50] O. Koch,et al. Structure-Based Design of Inhibitors of Protein–Protein Interactions: Mimicking Peptide Binding Epitopes , 2015, Angewandte Chemie.
[51] Matthew P. Jacobson,et al. Beyond cyclosporine A: conformation-dependent passive membrane permeabilities of cyclic peptide natural products. , 2015, Future medicinal chemistry.
[52] H. Kessler,et al. Enantiomeric cyclic peptides with different Caco-2 permeability suggest carrier-mediated transport. , 2015, Chemistry.
[53] Matthew P Jacobson,et al. Probing the Physicochemical Boundaries of Cell Permeability and Oral Bioavailability in Lipophilic Macrocycles Inspired by Natural Products. , 2015, Journal of medicinal chemistry.
[54] Andrew M Watkins,et al. Structure-based inhibition of protein-protein interactions. , 2015, European journal of medicinal chemistry.
[55] N. Tsomaia. Peptide therapeutics: targeting the undruggable space. , 2015, European journal of medicinal chemistry.
[56] Yang Wang,et al. N-terminal and C-terminal modulation of Hsp90 produce dissimilar phenotypes. , 2015, Chemical communications.
[57] T. A. Hill,et al. Fixierung cyclischer Peptide: Mimetika von Proteinstrukturmotiven , 2014 .
[58] D. Fairlie,et al. Constraining cyclic peptides to mimic protein structure motifs. , 2014, Angewandte Chemie.
[59] David J. Craik,et al. Rational design and synthesis of an orally bioavailable peptide guided by NMR amide temperature coefficients , 2014, Proceedings of the National Academy of Sciences.
[60] D. Craik,et al. Improving on nature: making a cyclic heptapeptide orally bioavailable. , 2014, Angewandte Chemie.
[61] J. Wells,et al. Small-molecule inhibitors of protein-protein interactions: progressing toward the reality. , 2014, Chemistry & biology.
[62] A. Ganesan,et al. Total synthesis and biological evaluation of PF1171A, C, F, and G, cyclic hexapeptides with insecticidal activity. , 2014, The Journal of organic chemistry.
[63] G. Goetz,et al. EPSA: A Novel Supercritical Fluid Chromatography Technique Enabling the Design of Permeable Cyclic Peptides. , 2014, ACS medicinal chemistry letters.
[64] Martin J. Stoermer,et al. Cyclic Penta- and Hexaleucine Peptides without N-Methylation Are Orally Absorbed. , 2014, ACS medicinal chemistry letters.
[65] J. Bajorath,et al. Polypharmacology: challenges and opportunities in drug discovery. , 2014, Journal of medicinal chemistry.
[66] Dima Kozakov,et al. How Proteins Bind Macrocycles , 2014, Nature chemical biology.
[67] N. Selner,et al. Early Endosomal Escape of a Cyclic Cell-Penetrating Peptide Allows Effective Cytosolic Cargo Delivery , 2014, Biochemistry.
[68] S. McAlpine,et al. A heat shock protein 90 inhibitor that modulates the immunophilins and regulates hormone receptors without inducing the heat shock response. , 2014, Bioorganic & medicinal chemistry letters.
[69] Serge Zaretsky,et al. Exocyclic control of turn induction in macrocyclic peptide scaffolds. , 2013, Chemistry.
[70] S. Sagan,et al. Cell‐penetrating peptides: 20 years later, where do we stand? , 2013, FEBS letters.
[71] Horst Kessler,et al. N-methylation of peptides and proteins: an important element for modulating biological functions. , 2013, Angewandte Chemie.
[72] H. Kessler,et al. N‐Methylierung von Peptiden und Proteinen: ein wichtiges Element für die Regulation biologischer Funktionen , 2013 .
[73] D. Craik,et al. The Future of Peptide‐based Drugs , 2013, Chemical biology & drug design.
[74] I. Khanna. Drug discovery in pharmaceutical industry: productivity challenges and trends. , 2012, Drug discovery today.
[75] Yizhong Zhang,et al. Optimizing PK properties of cyclic peptides: the effect of side chain substitutions on permeability and clearance(). , 2012, MedChemComm.
[76] I. Toth,et al. Peptides as therapeutics with enhanced bioactivity. , 2012, Current medicinal chemistry.
[77] K. Jolliffe,et al. Synthesis of sansalvamide A peptidomimetics: triazole, oxazole, thiazole, and pseudoproline containing compounds. , 2012, Tetrahedron.
[78] J. Ge,et al. Clinical Use of Aspirin in Treatment and Prevention of Cardiovascular Disease , 2011, Thrombosis.
[79] Li Di,et al. Development of a new permeability assay using low-efflux MDCKII cells. , 2011, Journal of pharmaceutical sciences.
[80] Yizhong Zhang,et al. On-resin N-methylation of cyclic peptides for discovery of orally bioavailable scaffolds , 2011, Nature chemical biology.
[81] Hannu Raunio,et al. Prodrugs—from Serendipity to Rational Design , 2011, Pharmacological Reviews.
[82] Philippe Roche,et al. Chemical and structural lessons from recent successes in protein-protein interaction inhibition (2P2I). , 2011, Current opinion in chemical biology.
[83] Douglas B Kell,et al. Pharmaceutical drug transport: the issues and the implications that it is essentially carrier-mediated only. , 2011, Drug discovery today.
[84] Christopher J. White,et al. Contemporary strategies for peptide macrocyclization. , 2011, Nature chemistry.
[85] Gert Storm,et al. Endosomal escape pathways for delivery of biologicals. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[86] D. Kingston. Modern natural products drug discovery and its relevance to biodiversity conservation. , 2011, Journal of natural products.
[87] H. Kessler,et al. The effect of multiple N-methylation on intestinal permeability of cyclic hexapeptides. , 2011, Molecular pharmaceutics.
[88] T. Joh,et al. Involvement of oxidative stress and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in inflammatory bowel disease , 2011, Journal of clinical biochemistry and nutrition.
[89] Peter Buchwald,et al. Small‐molecule protein–protein interaction inhibitors: Therapeutic potential in light of molecular size, chemical space, and ligand binding efficiency considerations , 2010, IUBMB life.
[90] Li Di,et al. Coexistence of passive and carrier-mediated processes in drug transport , 2010, Nature Reviews Drug Discovery.
[91] R. King. Biotransformations in Drug Metabolism , 2010 .
[92] C. Gilon,et al. The effect of backbone cyclization on PK/PD properties of bioactive peptide-peptoid hybrids: the melanocortin agonist paradigm. , 2010, Bioorganic & medicinal chemistry.
[93] Christian N. Cunningham,et al. Mechanistic studies of Sansalvamide A-amide: an allosteric modulator of Hsp90. , 2010, ACS medicinal chemistry letters.
[94] H. McMahon,et al. Mechanisms of endocytosis. , 2009, Annual review of biochemistry.
[95] E. Thines,et al. Anthranicine, an Unusual Cyclic Hexapeptide from Acremonium sp. A29-2004 , 2009 .
[96] A. Hopkins. Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.
[97] Ismael Zamora,et al. The Molecular Basis of CYP2D6-Mediated N-Dealkylation: Balance between Metabolic Clearance Routes and Enzyme Inhibition , 2008, Drug Metabolism and Disposition.
[98] H. Kessler,et al. N-methylation of peptides: a new perspective in medicinal chemistry. , 2008, Accounts of chemical research.
[99] G. Rishton,et al. Natural products as a robust source of new drugs and drug leads: past successes and present day issues. , 2008, The American journal of cardiology.
[100] H. Kessler,et al. Die Verbesserung der oralen Bioverfügbarkeit von Peptiden durch multiple N‐Methylierung: Somatostatin‐Analoga , 2008 .
[101] J. Brueggen,et al. Improving oral bioavailability of peptides by multiple N-methylation: somatostatin analogues. , 2008, Angewandte Chemie.
[102] D. Kell,et al. Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? , 2008, Nature Reviews Drug Discovery.
[103] Christopher L. McClendon,et al. Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.
[104] A. Barabasi,et al. Drug—target network , 2007, Nature Biotechnology.
[105] Richard W Roberts,et al. Design of cyclic peptides that bind protein surfaces with antibody-like affinity. , 2007, ACS chemical biology.
[106] P. Artursson,et al. Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers , 2007, Nature Protocols.
[107] Jian Yang,et al. Antiplatelet Agents Aspirin and Clopidogrel Are Hydrolyzed by Distinct Carboxylesterases, and Clopidogrel Is Transesterificated in the Presence of Ethyl Alcohol , 2006, Journal of Pharmacology and Experimental Therapeutics.
[108] Matthew P Jacobson,et al. Conformational flexibility, internal hydrogen bonding, and passive membrane permeability: successful in silico prediction of the relative permeabilities of cyclic peptides. , 2006, Journal of the American Chemical Society.
[109] C. Horvath,et al. Carbonyl- and sulfur-containing analogs of suberoylanilide hydroxamic acid: Potent inhibition of histone deacetylases. , 2006, Bioorganic & medicinal chemistry.
[110] Matthew P Jacobson,et al. Testing the conformational hypothesis of passive membrane permeability using synthetic cyclic peptide diastereomers. , 2006, Journal of the American Chemical Society.
[111] A. Cooke,et al. MAdCAM‐1 is needed for diabetes development mediated by the T cell clone, BDC‐2·5 , 2005, Immunology.
[112] L. Vassilev,et al. Targeting protein–protein interactions for cancer therapy , 2005, Journal of Molecular Medicine.
[113] M. Butler. Natural products to drugs: natural product-derived compounds in clinical trials. , 2005, Natural product reports.
[114] F. Koehn,et al. The evolving role of natural products in drug discovery , 2005, Nature Reviews Drug Discovery.
[115] Péter Csermely,et al. The efficiency of multi-target drugs: the network approach might help drug design. , 2004, Trends in pharmacological sciences.
[116] C. Lipinski. Lead- and drug-like compounds: the rule-of-five revolution. , 2004, Drug discovery today. Technologies.
[117] Mark S Butler,et al. The role of natural product chemistry in drug discovery. , 2004, Journal of natural products.
[118] I. Kola,et al. Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.
[119] David J Newman,et al. Natural products as sources of new drugs over the period 1981-2002. , 2003, Journal of natural products.
[120] S. Jois,et al. Design of β-turn Based Therapeutic Agents , 2003 .
[121] Leland J. Gershell,et al. A brief history of novel drug discovery technologies , 2003, Nature Reviews Drug Discovery.
[122] Gordon L Amidon,et al. A Mechanistic Approach to Understanding the Factors Affecting Drug Absorption: A Review of Fundamentals , 2002, Journal of clinical pharmacology.
[123] Stephen R. Johnson,et al. Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.
[124] C. Soto,et al. Converting a peptide into a drug: strategies to improve stability and bioavailability. , 2002, Current medicinal chemistry.
[125] W. Delano. Unraveling hot spots in binding interfaces: progress and challenges. , 2002, Current opinion in structural biology.
[126] R. Egleton,et al. Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability , 2001, Peptides.
[127] H. Kessler,et al. Design and Synthesis of Potent and Selective a 4 7 Integrin Antagonists , 2001 .
[128] P. Nelson,et al. A novel mechanism for chaperone-mediated telomerase regulation during prostate cancer progression. , 2001, Cancer research.
[129] D. Moody,et al. Variables in human liver microsome preparation: impact on the kinetics of l-alpha-acetylmethadol (LAAM) n-demethylation and dextromethorphan O-demethylation. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[130] H. Saito,et al. Structural requirements for determining the substrate affinity of peptide transporters PEPT1 and PEPT2 , 2000, Pflügers Archiv.
[131] A. Bogan,et al. Anatomy of hot spots in protein interfaces. , 1998, Journal of molecular biology.
[132] N. Krause. Copper-Catalyzed Enantioselective Michael Additions: Recent Progress with New Phosphorus Ligands. , 1998, Angewandte Chemie.
[133] N. Krause. Kupferkatalysierte enantioselektive Michael‐Additionen: jüngste Fortschritte mit neuen Phosphorliganden , 1998 .
[134] M. Rashidi,et al. In vitro oxidation of famciclovir and 6-deoxypenciclovir by aldehyde oxidase from human, guinea pig, rabbit, and rat liver. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[135] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .
[136] Ismael J. Hidalgo,et al. Carrier-mediated transport and efflux mechanisms in Caco-2 cells , 1996 .
[137] L. Presta,et al. Mucosal addressin cell adhesion molecule-1: a structural and functional analysis demarcates the integrin binding motif. , 1996, Journal of immunology.
[138] S. Clarke,et al. Role of aldehyde oxidase in the in vitro conversion of famciclovir to penciclovir in human liver. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[139] T. Clackson,et al. A hot spot of binding energy in a hormone-receptor interface , 1995, Science.
[140] L. Benet,et al. Pharmacokinetics of Famciclovir in Man , 1993 .
[141] R. Hodge. Famciclovir and Penciclovir. The Mode of Action of Famciclovir Including Its Conversion to Penciclovir , 1993 .
[142] L Wang,et al. Peptoids: a modular approach to drug discovery. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[143] H. Bundgaard. The utility of the prodrug approach to improve peptide absorption , 1992 .
[144] Ruth F. Nutt,et al. A potent cyclic hexapeptide analogue of somatostatin , 1981, Nature.
[145] G. Levy. Clinical pharmacokinetics of salicylates: a re-assessment. , 1980, British journal of clinical pharmacology.
[146] Nicole J. Yang,et al. Getting across the cell membrane: an overview for small molecules, peptides, and proteins. , 2015, Methods in molecular biology.
[147] T. Hoffmann,et al. Peptide therapeutics: current status and future directions. , 2015, Drug discovery today.
[148] C. Cabañas,et al. CXCR7 impact on CXCL12 biology and disease. , 2013, Trends in molecular medicine.
[149] R. Kineman,et al. Somatostatin and its receptors contribute in a tissue-specific manner to the sex-dependent metabolic (fed/fasting) control of growth hormone axis in mice. , 2011, American journal of physiology. Endocrinology and metabolism.
[150] W. Hooper,et al. Metabolism of diazepam and related benzodiazepines by human liver microsomes , 2010, European Journal of Drug Metabolism and Pharmacokinetics.
[151] K. Pang,et al. DMD #15321 Permeability, Transport, and Metabolism of Solutes in Caco-2 Cell Monolayers: A Theoretical Study , 2007 .
[152] Daniel R. Caffrey,et al. Structure-based maximal affinity model predicts small-molecule druggability , 2007, Nature Biotechnology.
[153] David C Fry,et al. Protein-protein interactions as targets for small molecule drug discovery. , 2006, Biopolymers.
[154] J. Lötsch. Opioid metabolites. , 2005, Journal of pain and symptom management.
[155] K. Richter,et al. Diazepam metabolism in human foetal and adult liver , 2004, European Journal of Clinical Pharmacology.
[156] K. Luthman,et al. Correlation of drug absorption with molecular surface properties. , 1996, Journal of pharmaceutical sciences.
[157] A. Harris,et al. Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. , 1994, Gut.
[158] S. Schreiber,et al. The mechanism of action of cyclosporin A and FK506. , 1992, Immunology today.
[159] P. Artursson,et al. Transport and permeability properties of human Caco-2 cells: An in vitro model of the intestinal epithelial cell barrier , 1990 .
[160] D. Kell,et al. Distributed under Creative Commons Cc-by 4.0 the Apparent Permeabilities of Caco-2 Cells to Marketed Drugs: Magnitude, and Independence from Both Biophysical Properties and Endogenite Similarities , 2022 .